Prevalence of renal insufficiency and factors associated among selected cancer patients on chemotherapy at Ocean Road Cancer Institute in Tanzania: a cross-sectional study.
Cancer
Chemotherapy
Creatinine clearance
Ocean Road Cancer Institute
Renal insufficiency
Journal
BMC cancer
ISSN: 1471-2407
Titre abrégé: BMC Cancer
Pays: England
ID NLM: 100967800
Informations de publication
Date de publication:
25 Jun 2024
25 Jun 2024
Historique:
received:
15
10
2023
accepted:
23
05
2024
medline:
26
6
2024
pubmed:
26
6
2024
entrez:
25
6
2024
Statut:
epublish
Résumé
Cancer is among the leading cause of death worldwide. Chemotherapy is commonly used in cancer management and among the challenges in managing cancer patients is renal insufficiency (RI), which can be due to cancer or anticancer treatment and can be potentiated by different factors. Data regarding the prevalence of RI and associated factors in Tanzania is scanty. This study aims to assess the prevalence of RI and associated factors among selected cancer patients on chemotherapy. This analytical cross-sectional study was conducted at Ocean Road Cancer Institute (ORCI) in Dar es Salaam, Tanzania, from March to May 2023. The study included cancer patients on chemotherapy. Data was collected using semi-structured questionnaires whereby socio-demographics, clinical and laboratory data were recorded. Data was analyzed by using STATA version 15. Categorical data was presented as frequencies and percentages, and continuous data was summarized using means. A modified Poisson regression model was used to assess factors associated with RI. The p-values ≤ 0.05 was considered statistically significant. Out of 354 patients, the majority (76.6%) were female. The enrolled patients' mean age was 53 ± 13.19 years. The proportion of cancer patients with RI was 62.2% with most (60%) having stage 2 and stage 3 (37.7%). Age, hypertension (HTN), human immunodeficiency virus (HIV), diabetes mellitus (DM) and non-steroidal anti-inflammatory drugs (NSAIDs) use were significantly associated with increased risk of RI (p ≤ 0.05). This study showed that RI is common among cancer patients on chemotherapy. Age, HTN, DM, HIV and NSAIDS use were associated with RI. Close monitoring of kidney function is necessary for cancer patients with other factors associated with RI. Use of creatinine clearance (CrCl) rather than serum creatinine in estimating kidney function is important.
Sections du résumé
BACKGROUND
BACKGROUND
Cancer is among the leading cause of death worldwide. Chemotherapy is commonly used in cancer management and among the challenges in managing cancer patients is renal insufficiency (RI), which can be due to cancer or anticancer treatment and can be potentiated by different factors. Data regarding the prevalence of RI and associated factors in Tanzania is scanty. This study aims to assess the prevalence of RI and associated factors among selected cancer patients on chemotherapy.
METHODS
METHODS
This analytical cross-sectional study was conducted at Ocean Road Cancer Institute (ORCI) in Dar es Salaam, Tanzania, from March to May 2023. The study included cancer patients on chemotherapy. Data was collected using semi-structured questionnaires whereby socio-demographics, clinical and laboratory data were recorded. Data was analyzed by using STATA version 15. Categorical data was presented as frequencies and percentages, and continuous data was summarized using means. A modified Poisson regression model was used to assess factors associated with RI. The p-values ≤ 0.05 was considered statistically significant.
RESULTS
RESULTS
Out of 354 patients, the majority (76.6%) were female. The enrolled patients' mean age was 53 ± 13.19 years. The proportion of cancer patients with RI was 62.2% with most (60%) having stage 2 and stage 3 (37.7%). Age, hypertension (HTN), human immunodeficiency virus (HIV), diabetes mellitus (DM) and non-steroidal anti-inflammatory drugs (NSAIDs) use were significantly associated with increased risk of RI (p ≤ 0.05).
CONCLUSION
CONCLUSIONS
This study showed that RI is common among cancer patients on chemotherapy. Age, HTN, DM, HIV and NSAIDS use were associated with RI. Close monitoring of kidney function is necessary for cancer patients with other factors associated with RI. Use of creatinine clearance (CrCl) rather than serum creatinine in estimating kidney function is important.
Identifiants
pubmed: 38918707
doi: 10.1186/s12885-024-12419-y
pii: 10.1186/s12885-024-12419-y
doi:
Substances chimiques
Antineoplastic Agents
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
763Informations de copyright
© 2024. The Author(s).
Références
World Health Organization (WHO). Cancer fact sheets [Internet]. 2022 [cited 2022 Oct 14]. https://www.who.int/news-room/fact-sheets/detail/cancer .
Lameire N. Nephrotoxicity of recent anti-cancer agents. Clin Kidney J. 2014;7:11–22.
doi: 10.1093/ckj/sft135
pubmed: 25859345
Guo K, Wang Z, Luo R, Cheng Y, Ge S, Xu G. Association between chronic kidney disease and cancer including the mortality of cancer patients: national health and nutrition examination survey 1999–2014. Am J Transl Res. 2022;14:2356–66.
pubmed: 35559400
pmcid: 9091102
Pontes L, Antunes Y, Bugano D, Karnakis T, Giglio A, Kaliks R. Prevalence of renal insufficiency in elderly cancer patients in a tertiary cancer center. Einstein. 2014;12:300–3.
doi: 10.1590/s1679-45082014ao3003
pubmed: 25295449
pmcid: 4872939
Manyau P, Mabeka M, Mudzviti T, Kadzatsa W, Nyamhunga A. Renal function impairment in cervical cancer patients treated with cisplatin-based chemoradiation: a review of medical records in a Zimbabwean outpatient department. PLoS ONE. 2021;16:1–9.
doi: 10.1371/journal.pone.0245383
Janus N, Launay-Vacher V, Byloos E, MacHiels J, Duck L, Kerger J, et al. Cancer and renal insufficiency results of the BIRMA study. Br J Cancer. 2010;103:1815–21.
doi: 10.1038/sj.bjc.6605979
pubmed: 21063408
pmcid: 3008606
Chen J, Wang X, Luo P, He Q. Effects of unidentified renal insufficiency on the safety and efficacy of chemotherapy for metastatic colorectal cancer patients: a prospective, observational study. Support Care Cancer. 2015;23:1043–8.
doi: 10.1007/s00520-014-2461-3
pubmed: 25277961
Stengel B. Chronic kidney disease and cancer: a troubling connection. J Nephrol. 2010;23:253–62.
pubmed: 20349418
pmcid: 4823382
McMahon B, Rosner M. GFR measurement and chemotherapy dosing in patients with kidney disease and cancer. Kidney360. 2020;1:141–50.
doi: 10.34067/KID.0000952019
pubmed: 35372903
pmcid: 8809099
Launay-Vacher V, Janus N, Deray G. Renal insufficiency and cancer treatments. ESMO Open. 2016;1:1–6.
doi: 10.1136/esmoopen-2016-000091
Kidney Disease Improving Global Outcomes (KDIGO). Clinical practice Guideline for the evaluation and management of chronic kidney disease. Off J Int Soc Nephrol. 2013;3:1–163.
Krens SD, Lassche G, Jansman FGA, Desar IME, Lankheet NAG, Burger DM, et al. Review dose recommendations for anticancer drugs in patients with renal or hepatic impairment. Lancet Oncol. 2019;20:e200–7.
doi: 10.1016/S1470-2045(19)30145-7
pubmed: 30942181
Costalonga EC, Coelho FO, Caires RA, Burdmann EA. Assessment of kidney function in patients with Cancer. adv Chronic Kidney Dis. 2018;25:49–56.
doi: 10.1053/j.ackd.2017.10.010
pubmed: 29499887
Malyszko J, Tesarova P, Capasso G, Capasso A. Review the link between kidney disease and cancer: complications and treatment. Lancet. 2020;396:277–87.
doi: 10.1016/S0140-6736(20)30540-7
pubmed: 32711803
Lameire NH, Flombaum CD, Moreau D, Ronco C, Lameire NH, Flombaum CD, et al. Acute renal failure in cancer patients acute renal failure in cancer patients. Ann Med. 2009;37:13–25.
doi: 10.1080/07853890510007205
Launay-Vacher V, Gligorov J, Le tourneau C, Janus N, Spano J, Ray-Coquard I. Prevalence of renal insufficiency in breast cancer patients and related pharmacological issues. Breast Cancer Res Treat. 2010;124:745–53.
doi: 10.1007/s10549-008-0131-1
pubmed: 18704681
Launay-Vacher V, Oudard S, Janus N, Gligorov J, Pourrat X, Rixe O, et al. Prevalence of renal insufficiency in cancer patients and implications for anticancer drug management: the renal insufficiency and anticancer medications (IRMA) study. Cancer. 2007;110:1376–84.
doi: 10.1002/cncr.22904
pubmed: 17634949
Lotan E, Leader A, Lishner M, Gottfried M, Pereg D. Unrecognized renal insufficiency and chemotherapy-associated adverse effects among breast cancer patients. Anticancer Drugs. 2012;23:991–5.
doi: 10.1097/CAD.0b013e328355dd8a
pubmed: 22728764
Singh S, Dhasmana D, Bisht M, Singh P. Pattern of adverse drug reactions to anticancer drugs: a quantitative and qualitative analysis. Indian J Med Pediatr Oncol. 2017;38:140–5.
Belachew S, Erku D, Mekuria A, Gebresillassie B. Pattern of chemotherapy-related adverse effects among adult cancer patients treated at Gondar university referral hospital, Ethiopia : a cross- sectional study. Drug Healthc Patient Saf. 2016;8:83–90.
doi: 10.2147/DHPS.S116924
pubmed: 27994485
pmcid: 5153262
World Health Organization/ International Agency for Research on Cancer (IARC). Tanzania fact sheets globocan 2020. Int Dir Build Res Inf Dev Organ. 2020;220–220.
Mathur P, Sathishkumar K, Chaturvedi M, Das P, Sudarshan KL, Santhappan S et al. Cancer statistics, 2020: Report from National Cancer Registry Programme, India. JCO Glob Oncol. 2020;(6):1063–75.
Fowler H, Belot A, Ellis L, Maringe C, Luque-fernandez MA, Njagi EN, et al. Comorbidity prevalence among cancer patients: a population-based cohort study of four cancers. BMC Cancer. 2020;20:1–15.
doi: 10.1186/s12885-019-6472-9
Hannan M, Ansari S, Meza N, Anderson AH, Srivastava A, Waikar S, et al. Risk factors for CKD progression overview of findings from the CRIC Study. CJASN. 2021;16:1–12.
doi: 10.2215/CJN.07830520
Leblanc M, Kellum JA, Gibney RTN, Lieberthal W, Tumlin J, Mehta R. Risk factors for acute renal failure: inherent and modifiable risks. 2005;11:533–6.
Aapro M, Launay-vacher V. Importance of monitoring renal function in patients with cancer. Cancer Treat Rev. 2012;38:235–40.
doi: 10.1016/j.ctrv.2011.05.001
pubmed: 21605937
Strati P, Chaffee K, Achenbach S. Renal insufficiency is an independent prognostic factor in patients with chronic lymphocytic leukemia. Haematologica. 2017;7:22–5.
doi: 10.3324/haematol.2016.150706
Yan Y, Li H, Zhou Q, Peng Z, An X, Li W, et al. Renal function and all-cause Mortality Risk among Cancer patients. Med (Baltim). 2016;95:1–8.
Bidani AK, Griffin KA. Pathophysiology of hypertensive renal damage implications for Therapy. Br Rev. 2004;44:595–601.
Klaus R, Niyazi M, Lange-Sperandio B. Radiation-induced kidney toxicity: molecular and cellular pathogenesis. Radiat Oncol [Internet]. 2021;16(1):1–11. https://doi.org/10.1186/s13014-021-01764-y .
Drożdżal S, Lechowicz K, Szostak B, Rosik J, Machoy KKA, Białecka MM, et al. Kidney damage from nonsteroidal anti-inflammatory drugs — myth or truth? Review of selected literature. Pharmacol Res Perspect. 2021;9:1–7.
doi: 10.1002/prp2.817
Hörl WH. Nonsteroidal anti-inflammatory drugs and the kidney. Pharmaceuticals. 2010;3:2291–321.
doi: 10.3390/ph3072291
pubmed: 27713354
pmcid: 4036662
Nazzal Z, Abdeljaleel F, Ashayer A, Salameh H, Hamdan Z. The rate and risk factors of acute kidney injury among cancer patients’ admissions in palestine: a single-center study. Int J Nephrol. 2022;22:1–6.
doi: 10.1155/2022/2972275